Who
John L. Lamattina
Director
Company insider
Files Form 4 as: Director, Ligand Pharmaceuticals; Director, Immunome; Director, Larimar Therapeutics; Director, Human Genome Sciences; Director, Neurogen; Senior Vice President, Pfizer; Director, Thermo Fisher Scientific.
In numbers
- Trades disclosed
- 201
- Buys
- 4
- Sells
- 12
- Bought
- $250K
- Sold
- $9.5M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 15 Dec 2005
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $64K257 at $247.22 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $58K232 at $248.11 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $174K697 at $249.53 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $857K3,405 at $251.62 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $64K257 at $247.22 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $58K232 at $248.11 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $174K697 at $249.53 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $857K3,405 at $251.62 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 6 Mar 2026filed 31 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $247K2,161 at $114.15 | filing |
| 6 Mar 2026filed 31 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $434K2,161 at $200.76 | filing |
| 6 Mar 2026filed 31 Mar 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,161 at $0.00 | filing |
| 6 Mar 2026filed 31 Mar 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,161 at $0.00 | filing |
| 6 Mar 2026filed 31 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $247K2,161 at $114.15 | filing |
| 6 Mar 2026filed 31 Mar 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $434K2,161 at $200.76 | filing |
| 7 Nov 2025filed 12 Nov 2025 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,145 at $0.00 | filing |
| 7 Nov 2025filed 12 Nov 2025 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,034 at $0.00 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)LGND · tickerreport.com · 23 Oct 2026
0 headlines in the last 90 days name John L. Lamattina; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.